Combined application of parallel artificial membrane permeability assay and Caco-2 permeability assays in drug discovery

Journal of Pharmaceutical Sciences

Volumn 93, Issue 6, 2004, Pages 1440-1453

  Kerns, Edward H ^a   Di, Li ^a   Petusky, Susan ^a   Farris, Michele ^a   Ley, Rob ^a   Jupp, Phil ^a  

^a PFIZER INC   (United States)

Author keywords

Assay; Caco 2; Efflux; PAMPA; Permeability

Indexed keywords

AMOXICILLIN; ATENOLOL; CAFFEINE; CARBAMAZEPINE; CHLOROQUINE; CHLORPHENIRAMINE; CIMETIDINE; COLCHICINE; CYCLOSPORIN A; DACTINOMYCIN; DAUNORUBICIN; DEXAMETHASONE; DILTIAZEM; DIPYRIDAMOLE; EMETINE; ERYTHROMYCIN; ETOPOSIDE; FUROSEMIDE; HYDROCHLOROTHIAZIDE; KETOCONAZOLE; KETOPROFEN; MANNITOL; METOPROLOL; NAPROXEN; PHENAZONE; PROPRANOLOL; RANITIDINE; THEOPHYLLINE; UNINDEXED DRUG; VERAPAMIL;

ACTIVE TRANSPORT; ANALYTIC METHOD; ARTICLE; ARTIFICIAL MEMBRANE; CELL SECRETION; CORRELATION ANALYSIS; DRUG ABSORPTION; DRUG DIFFUSION; DRUG RESEARCH; GASTROINTESTINAL TRACT; HUMAN; HUMAN CELL; INHIBITION KINETICS; INTERMETHOD COMPARISON; MEMBRANE PERMEABILITY; MONOLAYER CULTURE; PARALLEL ARTIFICIAL MEMBRANE PERMEABILITY ASSAY; PH MEASUREMENT;

EID: 2642527944     PISSN: 00223549     EISSN: None     Source Type: Journal    
DOI: 10.1002/jps.20075     Document Type: Article

References (41)

1. Smith DA, van de Waterbeemd H. 1999. Pharmacokinetics and metabolism in early drug discovery. Curr Opin Chem Biol 3:373-378.
2. Krämer S. 1999. Absorption prediction from physicochemical parameters. Pharm Sci Technol Today 2:373-380.
3. Sinko JS. 1999. Drug selection in early drug development: Screening for acceptable pharmacokinetic properties using combined in vitro and computational approaches. Curr Opin Drug Discov Dev 2:42-48.
4. Kerns EH. 2001. High throughput physicochemical profiling for drug discovery. J Pharm Sci 90:1838-1858.
5. Caldwell GW. 2001. The new pre-preclinical paradigm: Compound optimization in early and late phase drug discovery. Curr Top Med Chem 1:353-366.
6. Avdeef A, Testa B. 2002. Physicochemical profiling in drug research: A brief survey of the state-of-the-art of experimental techniques. Cell Mol Life Sci 59:1681-1689.
7. Kerns EH, Di L. 2003. Pharmaceutical profiling in drug discovery. Drug Discov Today 7:316-323.
8. van de Waterbeemd H. 2001. Property-based design: Optimization of drug absorption and pharmacokinetics. J Med Chem 44:1313-1333.
9. Artursson P. 2001. Caco-2 monolayers in experimental and theoretical predictions of drug transport. Adv Drug Deliv Rev 46:27-43.
10. Hidalgo IJ. 2001. Assessing the absorption of new pharmaceuticals. Curr Top Med Chem 1:385-401.
11. Bohets H, Annaert P, Mannens G, Van Beijsterveldt L, Anciaux K, Verboven P, Meuldermans W, Lavrijsen K. 2001. Strategies for absorption screening in drug discovery and development. Curr Top Med Chem 1:367-383.
12. Lipinski CA. 2000. Drug-like properties and the causes of poor solubility and poor permeability. J Pharmacol Toxicol Methods 44:235-249.
13. Chong S, Dando SA, Morrison RA. 1997. Evaluation of biocoat intestinal epithelium differentiation environment (3-day cultured Caco-2 cells) as an absorption screening model with improved productivity. Pharm Res 14:1835-1837.
14. Menard CA. 2001. Comparison of Caco-2 permeability data in 24- and 96-well formats. Book of abstracts, LabAutomation 2001. January 2001, Palm Springs, CA.
15. Irvine JD, Takahashi L, Lockhart K, Cheong J, Tolan JW, Selick HE, Grove JR. 1999. MDCK (Madin-Darby canine kidney) cells: A tool for membrane permeability screening. J Pharm Sci 88:28-33.
16. Mandagere AK, Thompson TN, Hwang KK. 2002. Graphical model for estimating oral bioavailability of drugs in humans and other species from their Caco-2 permeability and in vitro liver enzyme metabolic stability rates. J Med Chem 45:304-311.
17. Artursson P. 2002. Prediction of drug absorption: Caco-2 and beyond. Book of abstracts, PAMPA 2002 Conference, San Francisco, CA.
18. Kansy M, Senner F, Gubernator K. 1998. Physicochemical high throughput screening: Parallel artificial membrane permeation assay in the description of passive absorption processes. J Med Chem 41:1007-1010.
19. Kansy M, Kratzat K, Parrilla I, Senner F, Wagner B. 2000. Physicochemical high throughput screening (pC-HTS): Determination of membrane permeability, partitioning and solubility. Molecular modeling and prediction of bioactivity. Proceedings of the 12th European Symposium on Quantitative Structure-Activity Relationships: Molecular modeling and prediction of bioactivity. 1998 Aug 23-28; Copenhagen, Denmark. New York: Kluwer Academic/Plenum Press, pp 237-243.
20. Avdeef A. 2001. Drug absorption in vitro model: Filter-immobilized artificial membranes. 2. Studies of the permeability properties of lactones in Piper methysticum Forst. Eur J Pharm Sci 14:271-280.
21. Zhu C, Jiang L, Chen TM, Hwang KK. 2002. A comparative study of artificial membrane permeability assay for high throughput profiling of drug absorption potential. Eur J Med Chem 37:399-407.
22. Wohnsland F, Faller B. 2001. High-throughput permeability pH profile and high-throughput alkane/water log P with artificial membranes. J Med Chem 44:923-930.
23. Balimane P, Langish R, Sanders M, Chong S. 2002. Parallel artificial membrane permeability assay: Improvements tuned toward early drug discovery screening. Abstracts of papers, PAMPA 2002 meeting. 2002 Jul 15-17; San Francisco, CA.
24. Di L, Kerns EH, Fan K, McConnell OJ, Carter G. 2003. High throughput artificial membrane permeability assay for blood-brain barrier. Eur J Med Chem 38:223-232.
25. Noppe M, van Dijck A, Mackie C, Brewster M. 2002. One year experience with PAMPA: Comparison between in silico data, PAMPA and animal data. Abstracts of papers, PAMPA 2002 meeting. 2002 Jul 15-17; San Francisco, CA.
26. Wood M, Barton P, Fessey R. Investigation of the physicochemical parameters of the parallel artificial membrane permeability assay (PAMPA) and their optimization for drug discovery. Abstracts of papers, PAMPA 2002 meeting. 2002 Jul 15-17; San Francisco, CA.
27. Chen HY. 2002. The integration of membrane permeability assay into a developability process for profiling early discovery compounds. Abstracts of papers, PAMPA 2002 meeting. 2002 Jul 15-17; San Francisco, CA.
28. Veber DF, Johnson SR, Cheng HY, Smith BR, Ward KW, Kopple KD. 2002. Molecular properties that influence the oral bioavailability of drug candidates. J Med Chem 45:2615-2623.
29. Sugano K, Hamada H, Machida M, Ushio H. 2001. High throughput prediction of oral absorption: Improvement of the composition of the lipid solution used in parallel artificial membrane permeation assay. J Biomol Screen 6:189-196.
30. Sugano K, Hamada H, Machida M, Ushio H, Saitoh K, Terada K. 2001. Optimized conditions of bio-mimetic artificial membrane permeability assay. Int J Pharm 228:181-188.
31. Sugano K, Takata N, Machida M, Saitoh K. 2002. Prediction of total passive permeation using bio-mimetic artificial membrane permeability and paracellular pathway model. J Pharm Sci Tech Jpn 62:240.
32. Obata K, Sugano K, Sato R, Machida M, Saitoh K. 2002. Profiling of oral drug absorption by high-throughput screening during the early drug discovery process. J Pharm Sci Tech Jpn 62:241.
33. Avdeef A. 2003. Absorption and drug development. Hoboken, NJ: Wiley-Interscience.
34. Avdeef A. 2001. Physicochemical profiling (solubility, permeability and charge state). Curr Top Med Chem 1:277-351.
35. Polli JW, Wring SA, Humphreys JE, Huang L, Morgan JB, Webster LO, Serabjit-Singh CS. 2001. Rational use of in vitro P-glycoprotein assays in drug discovery. J Pharmacol Exp Ther 299:620-628.
36. Stenberg P, Norinder U, Luthman K, Artursson P. 2001. Experimental and computational screening models for the prediction of intestinal drug absorption. J Med Chem 44:1927-1937.
37. McCall AL, Millington WR, Wurtman RJ. 1982. Blood-brain barrier transport of caffeine: Dose-related restriction of adenine transport. Life Sci 31:2709-2715.
38. Laitinen L, Kangas H, Kaukonen AM, Hakala K, Kotiaho T, Kostiainen R, Hirvonen J. 2003. N-in-one permeability studies of heterogeneous sets of compounds across Caco-2 cell monolayers. Pharm Res 20:187-197.
39. Fassen F, Vogel G, Spanings H, Vromans H. 2003. Caco-2 permeability, P-glycoprotein transport ratios and brain penetration of heterocyclic drugs. Int J Pharm 263:113-122.
40. Troutman MD, Thakker DR. 2003. Efflux ratio cannot assess P-glycoprotein-mediated attenuation of absorptive transport: Asymmetric effect of P-glycoprotein on absorptive and secretory transport across Caco-2 cell monolayers. Pharm Res 20:1200-1209.
41. Troutman MD, Thakker DR. 2003. Novel experimental parameters to quantify the modulation of absorptive and secretory transport of compounds by P-glycoprotein in cell culture models of intestinal epithelium. Pharm Res 20:1200-1209.